BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blanchard Z, Mullins N, Ellipeddi P, Lage JM, McKinney S, El-Etriby R, Zhang X, Isokpehi R, Hernandez B, Elshamy WM. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One 2014;9:e95663. [PMID: 24789045 DOI: 10.1371/journal.pone.0095663] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 López-mejía JA, Tallabs-utrilla LF, Salazar-sojo P, Mantilla-ollarves JC, Sánchez-carballido MA, Rocha-zavaleta L. c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment. IJMS 2022;23:8702. [DOI: 10.3390/ijms23158702] [Reference Citation Analysis]
2 Siddiqui A, Tumiati M, Joko A, Sandholm J, Roering P, Aakko S, Vainionpää R, Kaipio K, Huhtinen K, Kauppi L, Tuomela J, Hietanen S. Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition. Front Oncol 2021;11:733700. [PMID: 34616682 DOI: 10.3389/fonc.2021.733700] [Reference Citation Analysis]
3 Singh DD, Yadav DK. TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. Biomedicines 2021;9:876. [PMID: 34440080 DOI: 10.3390/biomedicines9080876] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Luttman JH, Colemon A, Mayro B, Pendergast AM. Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade. Cell Commun Signal 2021;19:59. [PMID: 34022881 DOI: 10.1186/s12964-021-00739-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Sami E, Bogan D, Molinolo A, Koziol J, ElShamy WM. The molecular underpinning of geminin-overexpressing triple-negative breast cancer cells homing specifically to lungs. Cancer Gene Ther 2021. [PMID: 33723406 DOI: 10.1038/s41417-021-00311-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Galván Morales MA, Barrera Rodríguez R, Santiago Cruz JR, Teran LM. Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. Molecules 2020;25:E5686. [PMID: 33276556 DOI: 10.3390/molecules25235686] [Reference Citation Analysis]
7 Ryan D, Koziol J, ElShamy WM. Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis. Sci Rep 2019;9:19150. [PMID: 31844158 DOI: 10.1038/s41598-019-55702-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cheng J, Guo J, North BJ, Tao K, Zhou P, Wei W. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis. Biochim Biophys Acta Rev Cancer 2019;1871:138-59. [PMID: 30602127 DOI: 10.1016/j.bbcan.2018.11.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
9 Campos-fernández E, Matsuo FS, Andrade MF, Servato JPS, Loyola AM, Cardoso SV, Siva SJ, Moraes ADS, de Faria PR. Prognostic value of histone H3 serine 10 phosphorylation and histone H4 lysine 12 acetylation in oral squamous cell carcinoma. Histopathology 2019;74:227-38. [DOI: 10.1111/his.13713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Tripathi R, Liu Z, Plattner R. EnABLing Tumor Growth and Progression: Recent progress in unraveling the functions of ABL kinases in solid tumor cells. Curr Pharmacol Rep 2018;4:367-79. [PMID: 30746323 DOI: 10.1007/s40495-018-0149-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Meirson T, Genna A, Lukic N, Makhnii T, Alter J, Sharma VP, Wang Y, Samson AO, Condeelis JS, Gil-Henn H. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget 2018;9:22158-83. [PMID: 29774130 DOI: 10.18632/oncotarget.25243] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
12 Ananthula S, Sinha A, El Gassim M, Batth S, Marshall GD Jr, Gardner LH, Shimizu Y, ElShamy WM. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers. Oncotarget 2016;7:20869-89. [PMID: 26989079 DOI: 10.18632/oncotarget.8029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Shao F, Sun H, Deng CX. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. Oncotarget. 2017;8:73329-73344. [PMID: 29069872 DOI: 10.18632/oncotarget.20274] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
14 Yoon J, Kim SB, Ahmed G, Shay JW, Terman JR. Amplification of F-Actin Disassembly and Cellular Repulsion by Growth Factor Signaling. Dev Cell 2017;42:117-129.e8. [PMID: 28689759 DOI: 10.1016/j.devcel.2017.06.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
15 Kushwaha PP, Rapalli KC, Kumar S. Geminin a multi task protein involved in cancer pathophysiology and developmental process: A review. Biochimie 2016;131:115-27. [PMID: 27702582 DOI: 10.1016/j.biochi.2016.09.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Jia LY, Shanmugam MK, Sethi G, Bishayee A. Potential role of targeted therapies in the treatment of triple-negative breast cancer. Anticancer Drugs 2016;27:147-55. [PMID: 26682525 DOI: 10.1097/CAD.0000000000000328] [Cited by in Crossref: 36] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
17 Wang J, Rouse C, Jasper JS, Pendergast AM. ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. Sci Signal. 2016;9:ra12. [PMID: 26838548 DOI: 10.1126/scisignal.aad3210] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
18 Guestini F, McNamara KM, Ishida T, Sasano H. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification. Expert Opin Ther Targets 2016;20:705-20. [PMID: 26607563 DOI: 10.1517/14728222.2016.1125469] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
19 Wang J, Pendergast AM. The Emerging Role of ABL Kinases in Solid Tumors. Trends Cancer. 2015;1:110-123. [PMID: 26645050 DOI: 10.1016/j.trecan.2015.07.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
20 Motawi TM, Sadik NA, Fahim SA, Shouman SA. Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact 2015;233:147-56. [PMID: 25863232 DOI: 10.1016/j.cbi.2015.03.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
21 Tökés A, Szász AM, Geszti F, Lukács LV, Kenessey I, Turányi E, Meggyesházi N, Molnár IA, Fillinger J, Soltész I, Bálint K, Hanzély Z, Arató G, Szendröi M, Kulka J. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases. J Clin Pathol 2015;68:274-82. [DOI: 10.1136/jclinpath-2014-202607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]